Co-stimulation

Results: 68



#Item
41CONTENTS EXECUTIVE SUMMARY ............................................................................................................. 2 1 BACKGROUND ...................................................................

CONTENTS EXECUTIVE SUMMARY ............................................................................................................. 2 1 BACKGROUND ...................................................................

Add to Reading List

Source URL: www.fda.gov

Language: English
42TITLE PAGE  Belatacept (BMS[removed]FDA’s Cardiovascular and Renal Drugs Advisory Committee

TITLE PAGE Belatacept (BMS[removed]FDA’s Cardiovascular and Renal Drugs Advisory Committee

Add to Reading List

Source URL: www.fda.gov

Language: English
43Ask the Expert  Michael S. Okun, M.D. Michael S. Okun, M.D., is the co-director of the Movement Disorders Center, Department of Neurology at the McKnight Brain Institute in Gainesville, Florida. The media buzz surroundin

Ask the Expert Michael S. Okun, M.D. Michael S. Okun, M.D., is the co-director of the Movement Disorders Center, Department of Neurology at the McKnight Brain Institute in Gainesville, Florida. The media buzz surroundin

Add to Reading List

Source URL: www.tsa-usa.org

Language: English - Date: 2011-08-03 15:43:43
44B R I E F C O M M U N I C AT I O N S  © 2009 Nature America, Inc. All rights reserved. Alefacept promotes co-stimulation blockade

B R I E F C O M M U N I C AT I O N S © 2009 Nature America, Inc. All rights reserved. Alefacept promotes co-stimulation blockade

Add to Reading List

Source URL: www.nature.com

Language: English - Date: 2010-02-12 10:42:35
45Curriculum Vitae for Academic Promotion The Johns Hopkins University School of Medicine Jonathan D. Powell, MD, PhD _____________________________ Jonathan D. Powell

Curriculum Vitae for Academic Promotion The Johns Hopkins University School of Medicine Jonathan D. Powell, MD, PhD _____________________________ Jonathan D. Powell

Add to Reading List

Source URL: www.fda.gov

Language: English
46Strategic Plan: Type 1 Diabetes Goals and Objectives immunetolerance.org General Principles Therapeutic intervention in T1D must interrupt the autoimmune response against islet antigens, coupled with regulation

Strategic Plan: Type 1 Diabetes Goals and Objectives immunetolerance.org General Principles Therapeutic intervention in T1D must interrupt the autoimmune response against islet antigens, coupled with regulation

Add to Reading List

Source URL: www.immunetolerance.org

Language: English - Date: 2014-09-24 12:23:01
47Transport Research Arena 2014, Paris  Evaluation of the Road Transport Management System, a selfregulation initiative in heavy vehicle transport in South Africa P A Nordengena* and O J Naidoob a CSIR Built Environment, P

Transport Research Arena 2014, Paris Evaluation of the Road Transport Management System, a selfregulation initiative in heavy vehicle transport in South Africa P A Nordengena* and O J Naidoob a CSIR Built Environment, P

Add to Reading List

Source URL: researchspace.csir.co.za

Language: English - Date: 2014-07-18 17:55:24
48Should I take abatacept (Orencia®) for rheumatoid arthritis? A Cochrane decision aid to discuss options with your doctor This decision aid is for you if: □ You are16 or older.

Should I take abatacept (Orencia®) for rheumatoid arthritis? A Cochrane decision aid to discuss options with your doctor This decision aid is for you if: □ You are16 or older.

Add to Reading List

Source URL: musculoskeletal.cochrane.org

Language: English - Date: 2011-03-22 09:38:52
49Microsoft Word - NCHC Abatacept Policy-finalterm12[removed]doc

Microsoft Word - NCHC Abatacept Policy-finalterm12[removed]doc

Add to Reading List

Source URL: www.ncdhhs.gov

Language: English - Date: 2012-02-29 09:11:19
50PRIOR AUTHORIZATION POLICY Orencia® (abatacept) Subcutaneous [SC] injection: To Initiate a Coverage Review, Call[removed]Intravenous [IV] infusion: To initiate a Coverage Review, Call[removed]OVERVIEW

PRIOR AUTHORIZATION POLICY Orencia® (abatacept) Subcutaneous [SC] injection: To Initiate a Coverage Review, Call[removed]Intravenous [IV] infusion: To initiate a Coverage Review, Call[removed]OVERVIEW

Add to Reading List

Source URL: statehealthplan.state.nc.us

Language: English - Date: 2014-08-12 13:02:41